Open Access5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming
Author(s) -
Philip J. Kuehl,
Carmen S. Tellez,
Marcie J. Grimes,
Thomas H. March,
Mathewos Tessema,
David Revelli,
Larry M. Mallis,
Wendy W. Dye,
Tyler Sniegowski,
Aaron Badenoch,
Michael Burke,
Devon Dubose,
David T. Vodak,
Maria A. Picchi,
Steven A. Belinsky
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0765-2
Subject(s) - medicine , pharmacokinetics , lung cancer , pharmacology , inhalation , dry powder inhaler , pathology , anesthesia , asthma , inhaler
Epigenetic therapy through demethylation of 5-methylcytosine has been largely ineffective in treating lung cancer, most likely due to poor tissue distribution with oral or subcutaneous delivery of drugs such as 5-azacytidine (5AZA). An inhalable, stable dry powder formulation of 5AZA was developed.